Trials / Terminated
TerminatedNCT01785771
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Intarcia Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c \>10% \</=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 60 mcg/day for 26 weeks plus optional 26-week extensions with continued treatment with ITCA 650 60 mcg/day
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ITCA 650 (exenatide in DUROS) |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2018-01-01
- Completion
- 2018-01-01
- First posted
- 2013-02-07
- Last updated
- 2019-03-07
Locations
51 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01785771. Inclusion in this directory is not an endorsement.